• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Low Rates of Local-Regional Recurrence in Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy.

作者信息

Adesoye Taiwo, Lucci Anthony

机构信息

Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Ann Surg Oncol. 2023 Oct;30(10):6243-6244. doi: 10.1245/s10434-023-14159-y. Epub 2023 Aug 23.

DOI:10.1245/s10434-023-14159-y
PMID:37610486
Abstract
摘要

相似文献

1
ASO Author Reflections: Low Rates of Local-Regional Recurrence in Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy.ASO作者反思：当代三联疗法治疗后炎性乳腺癌患者的局部区域复发率较低
Ann Surg Oncol. 2023 Oct;30(10):6243-6244. doi: 10.1245/s10434-023-14159-y. Epub 2023 Aug 23.
2
Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy.炎性乳腺癌患者接受当代三联疗法后局部区域复发率较低。
Ann Surg Oncol. 2023 Oct;30(10):6232-6240. doi: 10.1245/s10434-023-13906-5. Epub 2023 Jul 21.
3
ASO Author Reflections: The Multidisciplinary Approach to de Novo Metastatic Inflammatory Breast Cancer: A Combined Systemic and Locoregional Strategy.ASO作者反思：新发转移性炎性乳腺癌的多学科治疗方法：综合全身和局部区域策略
Ann Surg Oncol. 2021 Aug;28(8):4275-4276. doi: 10.1245/s10434-020-09421-6. Epub 2021 Jan 6.
4
ASO Author Reflections: Surgical Management Should be Considered in Patients with De Novo Stage IV Inflammatory Breast Cancer.ASO作者反思：初诊IV期炎性乳腺癌患者应考虑手术治疗。
Ann Surg Oncol. 2022 Oct;29(11):6689-6690. doi: 10.1245/s10434-022-12016-y. Epub 2022 Jun 14.
5
Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.炎性乳腺癌患者采用三联疗法治疗后发生局部区域性失败的风险因素。
Clin Breast Cancer. 2013 Oct;13(5):335-43. doi: 10.1016/j.clbc.2013.04.002. Epub 2013 Jul 10.
6
ASO Author Reflections: Surgical De-escalation for the Management of Ipsilateral Breast Cancer Recurrence in the Modern Era of Multimodality Treatment.美国骨科学会作者反思：在多模式治疗的现代时代，手术降级用于同侧乳腺癌复发的管理。
Ann Surg Oncol. 2022 Oct;29(10):6454-6455. doi: 10.1245/s10434-022-12310-9. Epub 2022 Jul 29.
7
ASO Author Reflections: AFP Levels at the Time of Recurrence Predict Post-recurrence Outcomes Irrespective of Modality Used to Treat Recurrence.ASO作者反思：复发时的甲胎蛋白水平可预测复发后的结局，无论用于治疗复发的方式如何。
Ann Surg Oncol. 2021 Nov;28(12):7684-7685. doi: 10.1245/s10434-021-09985-x. Epub 2021 Apr 20.
8
Inflammatory breast cancer, trimodal treatment, and mortality: Does where you live matter?炎性乳腺癌、三模式治疗与死亡率：居住地是否重要？
Surgery. 2022 Mar;171(3):687-692. doi: 10.1016/j.surg.2021.08.061. Epub 2021 Nov 30.
9
ASO Author Reflections: Effect Sizes of Whole Breast Radiotherapy and Systemic Therapies on Regional Recurrence Incidence in Breast Cancer Patients.ASO作者反思：全乳放疗和全身治疗对乳腺癌患者区域复发率的效应大小
Ann Surg Oncol. 2020 Sep;27(9):3412-3413. doi: 10.1245/s10434-020-08434-5. Epub 2020 Apr 4.
10
ASO Author Reflections: TNM 8th Edition: Stage I Non-small Cell Lung Cancer-Free from Recurrence and Adjuvant Therapy? How to Predict?ASO作者反思：《TNM第8版：Ⅰ期非小细胞肺癌——无复发及辅助治疗情况？如何预测？》
Ann Surg Oncol. 2019 Dec;26(Suppl 3):745-746. doi: 10.1245/s10434-019-07856-0. Epub 2019 Sep 25.

本文引用的文献

1
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.在 2 期和 3 期乳腺癌新辅助治疗中，个体水平病理完全缓解与无事件生存和远处无复发生存的相关性：I-SPY2 适应性随机临床试验的 3 年随访分析。
JAMA Oncol. 2020 Sep 1;6(9):1355-1362. doi: 10.1001/jamaoncol.2020.2535.
2
Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database.基于国家癌症数据库的数据探讨炎性乳腺癌的生物学亚型、治疗反应和结局。
Br J Surg. 2020 Jul;107(8):1033-1041. doi: 10.1002/bjs.11469. Epub 2020 Feb 14.
3
Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?非转移性炎性乳腺癌的预后是否比其他非转移性 T4 期癌症更差？
Cancer. 2018 Nov 15;124(22):4314-4321. doi: 10.1002/cncr.31757. Epub 2018 Oct 11.
4
The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.术前全身治疗后残留疾病对炎性乳腺癌患者临床结局的影响。
Ann Surg Oncol. 2017 Sep;24(9):2563-2569. doi: 10.1245/s10434-017-5903-6. Epub 2017 May 30.
5
Biology and management of inflammatory breast cancer.炎性乳腺癌的生物学特性与治疗策略
Expert Rev Anticancer Ther. 2010 Feb;10(2):209-20. doi: 10.1586/era.09.90.
6
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.炎性乳腺癌发病率及生存率趋势：美国国立癌症研究所的监测、流行病学与最终结果计划
J Natl Cancer Inst. 2005 Jul 6;97(13):966-75. doi: 10.1093/jnci/dji172.